Non-typeable Haemophilus influenzae airways infection: the next treatable trait in asthma? by Hinks, TSC, Brown, MA, Jabeen, M, Bharj, G

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide by Couillard, S, Laugerud, A, Jabeen, M, Ramakrishnan, S, Melhorn, J, Hinks, T, Pavord, I

A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE) by Couillard, S, Laugerud, A, Jabeen, M, Ramakrishnan, S, Melhorn, J, Hinks, TSC, Pavord, ID

Application of modern molecular microbiological techniques to identify treatable chronic bacterial airway infection in severe asthma by Jabeen, M, Street, T, Foster, D, Hood, D, Sanderson, N, Pavord, I, Klenerman, P, Hinks, T

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids while on monoclonal antibody therapy: protocol for a prospective observational study (BOOST) by Howell, I, Mahdi, M, Bafadhel, M, Hinks, TSC, Ramakrishnan, S, Melhorn, J, Jabeen, M, Pavord, ID

To what extent does the prototype ORACLE scale predict treatment benefits? Predicted versus observed impact of anti-inflammatory treatments by Couillard, S, Do, WIH, Beasley, R, Laugerud, A, Jabeen, M, Ramakrishnan, S, Melhorn, J, Hinks, TSC, Pavord, ID

The upper and lower airway microbiome in severe asthma by Jabeen, M, Sanderson, N, Barber, C, Lau, LCK, Pavord, ID, Chauhan, A, Klenerman, P, Street, T, Howarth, P, Hinks, TSC

A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial by Hinks, T, Barber, V, Black, J, Dutton, S, Jabeen, M, Melhorn, J, Rahman, N, Richards, D, Lasserson, D, Pavord, I, Bafadhel, M

Activation and in vivo evolution of the MAIT cell transcriptome in mice and humans reveals tissue repair functionality by Hinks, T, Marchi, E, Jabeen, M, Olshanksy, M, Kurioka, A, Pediongco, T, Meehan, B, Kostenko, L, Turner, S, Corbett, A, Chen, Z, Klenerman, P, McCluskey, J

Species-level, metagenomic and proteomic analysis of microbe-immune interactions in severe asthma by Jabeen, M, Sanderson, N, Tine, M, Donachie, G, Barber, C, Azim, A, Lau, L, Brown, T, Pavord, I, Chauhan, A, Klenerman, P, Street, T, Marchi, E, Howarth, P, Hinks, TC

Azithromycin for mild-to-moderate COVID-19: author's reply by Hinks, TSC, Cureton, L, Knight, R, Wang, A, Cane, JL, Barber, VS, Black, J, Dutton, SJ, Melhorn, J, Jabeen, M, Moss, P, Garlapati, R, Baron, T, Johnson, G, Cantle, F, Clarke, D, Elkhodair, S, Underwood, J, Lasserson, D, Pavord, ID, Morgan, S, Richards, D

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial by Hinks, TSC, Cureton, L, Knight, R, Wang, A, Cane, JL, Barber, VS, Black, J, Dutton, SJ, Melhorn, J, Jabeen, M, Moss, P, Garlapati, R, Baron, T, Johnson, G, Cantle, F, Clarke, D, Elkhodair, S, Underwood, J, Lasserson, D, Pavord, ID, Morgan, S, Richards, D

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial by Hinks, TSC, Cureton, L, Knight, R, Wang, A, Cane, JL, Barber, VS, Black, J, Dutton, SJ, Melhorn, J, Jabeen, M, Moss, P, Garlapati, R, Baron, T, Johnson, G, Cantle, F, Clarke, D, Elkhodair, S, Underwood, J, Lasserson, D, Pavord, ID, Morgan, SB, Richards, D